Novyra Pharmachem Initiates Capital Reduction to Write Off Accumulated Losses

Novyra Pharmachem Limited's paid-up capital will be reduced by ₹5.42 crore, while total accumulated losses stand at ₹5.70 crore.

Reader Takeaway: Balance sheet cleanup achieved; pivot to pharmaceuticals is key for future growth.

What just happened

Novyra Pharmachem Limited is implementing a Scheme of Capital Reduction under Section 66 of the Companies Act, 2013. The primary objective is to write off accumulated losses amounting to ₹5.425714 crore (₹542.5714 lakh). This will be achieved by cancelling 54,25,714 equity shares, representing a reduction of 7 shares held for every 1 share retained. The company clarifies this is a technical accounting adjustment with no cash payout to shareholders and no impact on operational assets.

Why this matters

This capital reduction serves as a balance sheet cleanup exercise. By removing negative reserves, the company's financial statements will appear cleaner. This is particularly significant given the company's strategic pivot from its former identity as Bansisons Tea Industries Limited to Novyra Pharmachem Limited, focusing on the pharmaceutical sector. The move aims to address past financial challenges and set a foundation for future viability in a new industry.

The backstory

The company, previously known as Bansisons Tea Industries Limited, has undergone a significant strategic shift. The main object clause was amended on December 29, 2025, to reflect its transition into the pharmaceutical sector. This pivot was driven by the agriculture sector's inability to provide adequate returns in recent years. The current capital reduction is a step to streamline its financial position post-transition.

What changes now

The capital reduction will effectively reduce the company's paid-up capital from ₹6.33 crore to ₹0.904286 crore. Accumulated losses of ₹5.425714 crore will be written off against the share capital account. This restructuring is expected to improve the appearance of the company's financial health, although it does not alter the underlying operational performance immediately.

Risks to watch

The success of Novyra Pharmachem hinges on its ability to execute its new strategy in the pharmaceutical sector. Past performance in the agriculture sector indicates challenges in generating sufficient returns. Investors will be closely watching the effectiveness of the new management team, led by the newly appointed Managing Director, in driving future revenue and profitability in the pharmaceutical domain.

Peer comparison

Information regarding specific pharmaceutical peers or their financial restructuring activities is not available in the filing. However, capital reduction is a common method for companies with significant accumulated losses to restructure their balance sheets before embarking on new growth phases or seeking fresh investment.

Context metrics

• Pre-reduction Paid-up Capital (as of March 31, 2026): ₹6.33 crore
• Post-reduction Paid-up Capital: ₹0.904286 crore
• Losses to be written off: ₹5.425714 crore
• Total Accumulated Losses (as of March 31, 2026): ₹5.7079348 crore

What to track next

Investors should monitor Novyra Pharmachem's progress in the pharmaceutical sector, focusing on revenue generation, profitability, and successful integration of the new business strategy. The performance of the new management team under Managing Director Mr. Anilkumar Amreliya will also be a key indicator.